Talk:Psoriatic arthritis

Contradiction

Discussion pointer: Talk:Psoriasis#Psoriatic arthritis. --Geniac (talk) 14:18, 6 August 2008 (UTC)

Prevalence and refs

The Psoriasis article and this one have differing prevalence ranges, with the Psoriasis one poorly sourced. While the PubMed search "prevalence of psoriatic arthritis (review[pt])" gave 155 results with respectively (2000:2012[dp]) 119 (2005:2012[dp]) 83 (17 freely available) for the date range restrictions.

• Prey S, Paul C, Bronsard V; et al. (2010). "Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature". J Eur Acad Dermatol Venereol. 24 (Suppl 2): 31–5. doi:10.1111/j.1468-3083.2009.03565.x. PMID 20443998. Psoriasis arthritis may affect up to 24% of psoriasis patients. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link) (quote from PubMed abstract)

Could someone with domain knowlege decide if any of these should go in

• Bowes J, Barton A (2010). "The genetics of psoriatic arthritis: lessons from genome-wide association studies". Discov Med. 10 (52): 177–83. PMID 20875338. {{cite journal}}: Unknown parameter |month= ignored (help)
• Dominguez P, Gladman DD, Helliwell P, Mease PJ, Husni ME, Qureshi AA (2010). "Development of screening tools to identify psoriatic arthritis". Curr Rheumatol Rep. 12 (4): 295–9. doi:10.1007/s11926-010-0113-2. PMID 20617467. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
• Kim N, Thrash B, Menter A (2010). "Comorbidities in psoriasis patients". Semin Cutan Med Surg. 29 (1): 10–5. doi:10.1016/j.sder.2010.01.002. PMID 20430302. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
• Naldi L, Mercuri SR (2010). "Epidemiology of comorbidities in psoriasis". Dermatol Ther. 23 (2): 114–8. doi:10.1111/j.1529-8019.2010.01304.x. PMID 20415817. {{cite journal}}: Unknown parameter |month= ignored (help)
• Laws P, Barton A, Warren RB (2010). "Psoriatic arthritis--what the dermatologist needs to know". J Eur Acad Dermatol Venereol. 24 (11): 1270–7. doi:10.1111/j.1468-3083.2010.03654.x. PMID 20384693. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
• Alamanos Y, Voulgari PV, Drosos AA (2008). "Incidence and prevalence of psoriatic arthritis: a systematic review". J. Rheumatol. 35 (7): 1354–8. PMID 18464305. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

RDBrown (talk) 14:43, 16 April 2011 (UTC)

Intent to revise page

Hello, I am a freelance writer working with the National Psoriasis Foundation to improve public education about psoriatic arthritis. The Foundation asked me to edit the wikipedia entry on this disease. It is my intention to use wikipedia's recommended outline for medical articles [1], and to incorporate the most current medically-reviewed information from the National Psoriasis Foundation and the Arthritis Foundation.

Please let me know if you have any thoughts on this!

amy stork NationalPsoriasisFoundation (talk) 22:38, 20 April 2011 (UTC)

The most important thing from my perspective is that you makes sure you follow WP:MEDRS. Otherwise welcome aboard.Doc James (talk · contribs · email) 23:43, 20 April 2011 (UTC)

Vitamin D therapy in psoriasis.

Araugo OE, Flowers FP, Brown K.

Vitamin D therapy in psoriasis.

DICP. 1991 Jul-Aug;25(7-8):835-9. Review.

PMID 1659041

Morimoto S, Yoshikawa K.

Psoriasis and vitamin D3. A review of our experience.

Arch Dermatol. 1989 Feb;125(2):231-4.

Abstract

Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D3) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D3 in both oral and topical ways in an open-design study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1 alpha,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D3 are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease.

PMID 2536537 Kamangar F, Koo J, Heller M, Lee E, Bhutani T.

Oral vitamin D, still a viable treatment option for psoriasis.

J Dermatolog Treat. 2012 Jan 21. [Epub ahead of print]

PMID 22103655

"The therapeutic use of vitamin D dates back to the 1930s when it was used as an oral agent for osteoporosis on a psoriasis patient who subsequently experienced clearing of psoriatic skin lesions.10 Dermatological application of topical vitamin D3 centers on the fact that the skin is both a site of initial vitamin D biosynthesis and a target for vitamin D3 activity causing modulation of keratinocytes and inflammatory mediators.11" [1]

FROM:

Grace K. Kim, DO

The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis; Where Does Topical Calcitriol Fit In?

J Clin Aesthet Dermatol. 2010 August; 3(8): 46–53.

PMC 2945865

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945865/ </ref>

Cites in above block quote:

10: Review Vitamin D analogs: mechanism of action and therapeutic applications.

Nagpal S, Lu J, Boehm MF

Curr Med Chem. 2001 Nov; 8(13):1661-79.

PMID 11562285

11: Wolverton SE.

Comprehensive Dermatologic Drug Therapy. 2nd Edition.

Philadephia, PA: Saunders Elsevier; 2007.

Morimoto S, Yoshikawa K.

Psoriasis and vitamin D3. A review of our experience.

Arch Dermatol. 1989 Feb;125(2):231-4.

Abstract

Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D3) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D3 in both oral and topical ways in an open-design study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1 alpha,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D3 are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease.

PMID 2536537

- history says the above list was added by Ocdnctx (talk) 9 May 2013‎

Br J Hosp Med

This is the best recent review article I could find.

Br J Hosp Med (Lond).
2016 Jul;77(7):C102-8.
doi: 10.12968/hmed.2016.77.7.C102.
Psoriatic arthritis.
Durham LE, Taams LS, Kirkham BW.
PMID 27388392
--Nbauman (talk) 22:18, 7 November 2016 (UTC)

Thanks, I'll see if I have access and try to incorporate it into the article. TylerDurden8823 (talk) 03:39, 30 March 2017 (UTC)

History

It would be helpful if there was an outline of the history of psoriatic arthritis in medicine (and how the history relates to psoriasis). PigeonChickenFish (talk) 04:22, 12 January 2024 (UTC)